S-1 Oral Anticancer Agent Improves Patients' Survival In Adjuvant Gastric Cancer Trial Versus Surgery Alone

Mon, 22 Jan 2007 02:00 PM EST

... Results of the large randomised phaseIII study (ACTS-GC) announced at the 2007 Gastrointestinal Cancers Symposium in Orlando,USA, showed that the oral anticancer agent S-1 reduced significantly the relative risk of death inearly stage gastric cancer patients by a significant 32 % as compared to curative surgery alone (p= 0.0024). [click link for full article] ...